By contrast, we discovered that NPmut HSPCs overexpressed CD74 (Figure 4C), whose increased expression correlates to the complete remission in patients with AML treated with the combined proteasome inhibitor bortezomib (Btz) and induction chemotherapy (52), as well as to Btz sensitivity in patients with multiple myeloma (53). Here, CD74 is linked to plasma cell myeloma.